Siplizumab Uses, Dosage, Side Effects and more
| Trade Name | Siplizumab |
| Generic | Siplizumab |
| Siplizumab Other Names | Siplizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
How Siplizumab works
Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.
